Genetic Testing Market by Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Application (Cancer diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4079364
- 247 Pages
- September 2020
- Pharmaceuticals
Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorders. There are various types of genetic testing and several methods such as cytogenetic testing, biochemical testing, molecular testing, and chromosome analysis used to determine changes in a person’s chromosomes, genes, or proteins. The results of a genetic tests confirm or diagnose a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder.
Genetic testing plays a vital role in determining the risk of developing certain diseases as well as screening and sometimes medical treatment. Different types of genetic testing are done for different reasons such as presymptomatic and predictive testing, carrier testing, prenatal testing, and newborn screening.
The global genetic testing market is expected to register substantial growth in the future, owing to rise in incidences of genetic disorders and cancer and rise in awareness & acceptance of personalized medicines. For instance, Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. For instance, Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure which leads to surge in demand for genetic testing in the region.
The global genetic testing market is segmented on the basis of type, technology, application, and region. By type, the market is categorized into predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, it is divided into cytogenetic testing/chromosomal analysis, biochemical testing, and molecular testing. Molecular testing is further classified into DNA sequencing and others. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. By region, the genetic testing market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major players in the genetic testing market are Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Type
o Predictive & Presymptomatic Testing
o Carrier Testing
o Prenatal & Newborn Testing
o Diagnostic Testing
o Pharmacogenomic Testing
o Others
• By Technology
o Cytogenetic Testing
o Biochemical Testing
o Molecular Testing
• By Application
o Cancer diagnosis
o Genetic Disease Diagnosis
o Cardiovascular Disease Diagnosis
o Others
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
• List of key players profiled in the report:
• Abbott Laboratories
• Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.)
• Myriad Genetics, Inc. (Myriad RBM, Inc.)
• Danaher Corporation (Cepheid)
• F. Hoffmann-La Roche Ltd.
• Eurofins Scientific
• Illumina, Inc.
• Qiagen N.V.
• Thermo Fisher Scientific, Inc.
• CSL Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• PerkinElmer, Inc.
• Natera
• Sonic Healthcare
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidences of genetic disorders and cancer
3.5.1.2.Rise in awareness & acceptance of personalized medicines
3.5.1.3.Advancements in genetic testing techniques
3.5.2.Restraints
3.5.2.1.Standardization concerns of genetic testing-based diagnostics
3.5.2.2.Stringent regulatory requirements for product approvals
3.5.3.Opportunities
3.5.3.1.Untapped emerging markets in developing countries
3.6.Patent analysis (2017–2022)
3.6.1.Patent analysis, by year
3.6.2.Patent analysis for year 2019, by country
CHAPTER 4:GENETIC TESTING MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast, by region
4.2.Predictive & presymptomatic testing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Carrier testing
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Prenatal and newborn testing
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Diagnostic testing
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Pharmacogenomic testing
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Others
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
CHAPTER 5:GENETIC TESTING MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast, by region
5.2.Cytogenetic testing/chromosome analysis
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Biochemical testing
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Molecular testing
5.4.1.Market size and forecast, by region, by type
5.4.1.1.DNA Sequencing
5.4.1.1.1.Market size and forecast, by region
5.4.1.2.Others
5.4.1.2.1.Market size and forecast, by region
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:GENETIC TESTING MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Cancer diagnosis
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Genetic disease diagnosis
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Cardiovascular disease diagnosis
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Others
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
CHAPTER 7:GENETIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by test type
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. market size and forecast, by test type
7.2.5.2.U.S. market size and forecast, by technology
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.Canada market size and forecast, by test type
7.2.5.5.Canada market size and forecast, by technology
7.2.5.6.Canada market size and forecast, by application
7.2.5.7.Mexico market size and forecast, by test type
7.2.5.8.Mexico market size and forecast, by technology
7.2.5.9.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by test type
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by country
7.3.5.1.Germany market size and forecast, by test type
7.3.5.2.Germany market size and forecast, by technology
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.France market size and forecast, by test type
7.3.5.5.France market size and forecast, by technology
7.3.5.6.France market size and forecast, by application
7.3.5.7.UK market size and forecast, by test type
7.3.5.8.UK market size and forecast, by technology
7.3.5.9.UK market size and forecast, by application
7.3.5.10.Italy market size and forecast, by test type
7.3.5.11.Italy market size and forecast, by technology
7.3.5.12.Italy market size and forecast, by application
7.3.5.13.Spain market size and forecast, by test type
7.3.5.14.Spain market size and forecast, by technology
7.3.5.15.Spain market size and forecast, by application
7.3.5.16.Rest of Europe market size and forecast, by test type
7.3.5.17.rest of Europe market size and forecast, by technology
7.3.5.18.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by test type
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by test type
7.4.5.2.Japan market size and forecast, by technology
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.China market size and forecast, by test type
7.4.5.5.China market size and forecast, by technology
7.4.5.6.China market size and forecast, by application
7.4.5.7.Australia market size and forecast, by test type
7.4.5.8.Australia market size and forecast, by technology
7.4.5.9.Australia market size and forecast, by application
7.4.5.10.India market size and forecast, by test type
7.4.5.11.India market size and forecast, by technology
7.4.5.12.India market size and forecast, by application
7.4.5.13.South Korea market size and forecast, by test type
7.4.5.14.South Korea market size and forecast, by technology
7.4.5.15.South Korea market size and forecast, by application
7.4.5.16.Rest of Asia-Pacific market size and forecast, by test type
7.4.5.17.Rest of Asia-Pacific market size and forecast, by technology
7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by test type
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by application
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil market size and forecast, by test type
7.5.5.2.Brazil market size and forecast, by technology
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Saudi Arabia market size and forecast, by test type
7.5.5.5.Saudi Arabia market size and forecast, by technology
7.5.5.6.Saudi Arabia market size and forecast, by application
7.5.5.7.South Africa market size and forecast, by test type
7.5.5.8.South Africa market size and forecast, by technology
7.5.5.9.South Africa market size and forecast, by application
7.5.5.10.Rest of LAMEA market size and forecast, by test type
7.5.5.11.Rest of LAMEA market size and forecast, by technology
7.5.5.12.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.CSL LTD.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.DANAHER CORPORATION (CEPHEID)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.EUROFINS SCIENTIFIC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.F. HOFFMANN-LA ROCHE LTD.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.ILLUMINA, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.QIAGEN N.V. (FORMULATRIX, INC.)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segment
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
TABLE 01.GLOBAL GENETIC TESTING MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02.GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE & PRESYMPTOMATIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL GENETIC TESTING MARKET FOR CARRIER TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL GENETIC TESTING MARKET FOR PRENATAL AND NEWBORN TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL GENETIC TESTING MARKET FOR DIAGNOSTIC TESTING BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL GENETIC TESTING MARKET FOR PHARMACOGENOMIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL GENETIC TESTING MARKET FOR OTHER TYPES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GENETIC TESTING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 09.GENETIC TESTING MARKET FOR CYTOGENETIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GENETIC TESTING MARKET FOR BIOCHEMICAL TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY TYPE, 2019–2027 ($MILLION)
TABLE 12.GENETIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GENETIC TESTING MARKET FOR OTHER MOLECULAR TESTS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GENETIC TESTING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.GENETIC TESTING MARKET FOR CANCER DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GENETIC TESTING MARKET FOR GENETIC DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GENETIC TESTING MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 19.GENETIC TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GENETIC TESTING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 21.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 22.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.U.S. GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 26.U.S. GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 27.U.S. GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 28.CANADA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 29.CANADA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 30.CANADA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 31.MEXICO GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 33.MEXICO GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 34.EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 35.EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 36.EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 37.EUROPE GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 38.GERMANY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 39.GERMANY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 40.GERMANY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 41.FRANCE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 42.FRANCE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 43.FRANCE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 44.UK GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 45.UK GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 46.UK GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 47.ITALY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 48.ITALY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 49.ITALY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 50.SPAIN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 51.SPAIN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 52.SPAIN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 56.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.JAPAN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 61.JAPAN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 62.JAPAN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 63.CHINA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 64.CHINA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 65.CHINA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 69.INDIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 70.INDIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 71.INDIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 72.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 78.LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 79.LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 80.LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 81.LAMEA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 82.BRAZIL GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 83.BRAZIL GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 84.BRAZIL GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 86.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 89.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 90.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 92.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 93.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 94.ABBOTT: COMPANY SNAPSHOT
TABLE 95.ABBOTT: OERATING SEGMENT
TABLE 96.ABBOTT: PRODUCT PORTFOLIO
TABLE 97.BIO-RAD: COMPANY SNAPSHOT
TABLE 98.BIO-RAD: OPERATING SEGMENTS
TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.CSL LTD: COMPANY SNAPSHOT
TABLE 101.CSL LTD..: OPERATING SEGMENT
TABLE 102.CSL LTD..: PRODUCT PORTFOLIO
TABLE 103.DANAHER: COMPANY SNAPSHOT
TABLE 104.DANAHER: OPERATING SEGMENTS
TABLE 105.DANAHER: PRODUCT PORTFOLIO
TABLE 106.EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 107.EUROFINS SCIENTIFIC.: PRODUCT PORTFOLIO
TABLE 108.ROCHE: COMPANY SNAPSHOT
TABLE 109.ROCHE: OPERATING SEGMENT
TABLE 110.ROCHE: PRODUCT PORTFOLIO
TABLE 111.ILLUMINA: COMPANY SNAPSHOT
TABLE 112.ILLUMINA: OPERATING SEGMENTS
TABLE 113.ILLUMINA: PRODUCT PORTFOLIO
TABLE 114.MYRIAD: COMPANY SNAPSHOT
TABLE 115.MYRIAD: OPERATING SEGMENTS
TABLE 116.MYRIAD: PRODUCT PORTFOLIO
TABLE 117.QIAGEN: COMPANY SNAPSHOT
TABLE 118.QIAGEN: PRODUCT SEGMENT
TABLE 119.QIAGEN: PRODUCT PORTFOLIO
TABLE 120.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 121.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
TABLE 122.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
